Knowledge Mapping of Exosomes in Autoimmune Diseases: A Bibliometric Analysis (2002–2021)

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Июль 22, 2022

Background Autoimmune diseases (AIDs) are a class of chronic disabling characterized by inflammation and damage to muscles, joints, bones, internal organs. Recent studies have shown that much progress has been made in the research exosomes AIDs. However, there is no bibliometric analysis this field. This study aims provide comprehensive overview knowledge structure hotspots AIDs through bibliometrics. Method Publications related from 2002 2021 were searched on web science core collection (WoSCC) database. VOSviewers, CiteSpace R package “bibliometrix” used conduct analysis. Results 312 articles 48 countries led China United States included. The number publications increasing year year. Central South University, Sun Yat Sen Tianjin Medical University Pennsylvania main institutions. Frontiers immunology most popular journal field, Journal Immunology co-cited journal. These come 473 authors among which Ilias Alevizos, Qianjin Lu, Wei Wei, Jim Xiang Ming Zhao had published papers Clotilde Théry was often. Studying mechanism endogenous occurrence development therapeutic strategy exogenous topics “Mesenchymal stem cells”, “microRNA”, “biomarkers”, “immunomodulation”, “therapy” primary keywords emerging hotspots. Conclusion first comprehensively summarizes trends developments information identifies recent frontiers hot directions, will reference for scholars studying exosomes.

Язык: Английский

---

Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases

Cells, Год журнала: 2022, Номер 11(15), С. 2300 - 2300

Опубликована: Июль 26, 2022

Immune-mediated inflammatory diseases (IMIDs) encompass several entities such as “classic” autoimmune disorders or immune-mediated with autoinflammatory characteristics. Adult stem cells including mesenchymal (MSCs) are by far the most commonly used type in clinical practice. However, due to possible side effects of MSC-based treatments, there is an increase interest MSC-secretome (containing large extracellular vesicles, microvesicles, and exosomes) alternative therapeutic option IMIDs. A wide spectrum MSC-secretome-related biological activities has been proven thus anti-inflammatory, anti-apoptotic, immunomodulatory properties. In comparison MSCs, secretome less immunogenic but exerts similar actions, so it can be considered ideal cell-free alternative. Additionally, since composition engineered, for a future perspective, could also viewed part potential delivery system within nanomedicine, allowing us specifically target dysfunctional tissues. Although many encouraging results from pre-clinical studies have recently obtained that strongly support application IMIDs, human administration still their infancy. This article reviews IMIDs provides insight into interpretation its beneficial actions.

Язык: Английский

---

Understanding exosomes: Part 2—Emerging leaders in regenerative medicine

Periodontology 2000, Год журнала: 2024, Номер 94(1), С. 257 - 414

Опубликована: Фев. 1, 2024

Abstract Exosomes are the smallest subset of extracellular signaling vesicles secreted by most cells with ability to communicate other tissues and cell types over long distances. Their use in regenerative medicine has gained tremendous momentum recently due their be utilized as therapeutic options for a wide array diseases/conditions. Over 5000 publications currently being published yearly on this topic, number is only expected dramatically increase novel strategies continue developed. Today exosomes have been applied numerous contexts including neurodegenerative disorders (Alzheimer's disease, central nervous system, depression, multiple sclerosis, Parkinson's post‐traumatic stress disorders, traumatic brain injury, peripheral nerve injury), damaged organs (heart, kidney, liver, stroke, myocardial infarctions, ovaries), degenerative processes (atherosclerosis, diabetes, hematology musculoskeletal degeneration, osteoradionecrosis, respiratory disease), infectious diseases (COVID‐19, hepatitis), procedures (antiaging, bone regeneration, cartilage/joint osteoarthritis, cutaneous wounds, dental dermatology/skin erectile dysfunction, hair regrowth, intervertebral disc repair, spinal cord vascular regeneration), cancer therapy (breast, colorectal, gastric osteosarcomas), immune function (allergy, autoimmune regulation, inflammatory diseases, lupus, rheumatoid arthritis). This scoping review first its kind aimed at summarizing extensive potential broad range disorders.

Язык: Английский

---

Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature

Regenerative Therapy, Год журнала: 2022, Номер 21, С. 527 - 539

Опубликована: Окт. 31, 2022

Hair loss, or alopecia, is associated with several psychosocial and medical comorbidities, it remains an economic burden to individuals the society. Alopecia attributable varied mechanisms features a multifactorial predisposition, available conventional interventions have limitations. Thus, therapeutic strategies for alopecia in regenerative medicine are currently being explored, increasing evidence suggesting that mesenchymal stem cell (MSC) implantation, MSC-derived secretome treatment, blood-derived platelet-rich plasma therapies potential treatment options. In this review, we searched Cochrane Library, MEDLINE (PubMed), EMBASE, Scopus using various combinations of terms, such as “stem cell,” “alopecia,” “hair loss,” “Androgenetic alopecia,” “male-pattern hair “female-pattern “regenerative growth,” “cell therapy,” “mesenchymal cells,” “MSC-derived extracellular vesicles,” exosomes,” “platelet-rich plasma” summarized most promising treatments alopecia. Moreover, further opportunities improving efficacy innovative promoting clinical application were discussed.

Язык: Английский

---

Therapeutic Strategy of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles as Regenerative Medicine

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(12), С. 6480 - 6480

Опубликована: Июнь 9, 2022

Extracellular vesicles (EVs) are lipid bilayer membrane particles that play critical roles in intracellular communication through EV-encapsulated informative content, including proteins, lipids, and nucleic acids. Mesenchymal stem cells (MSCs) pluripotent with self-renewal ability derived from bone marrow, fat, umbilical cord, menstruation blood, pulp, etc., which they use to induce tissue regeneration by their direct recruitment into injured tissues, the heart, liver, lung, kidney, or secreting factors, such as vascular endothelial growth factor insulin-like factor. Recently, MSC-derived EVs have been shown regenerative effects against various diseases, partially due post-transcriptional regulation of target genes miRNAs. Furthermore, garnered attention novel drug delivery systems, because can specially encapsulate molecules. In this review, we summarize molecular mechanisms EVs.

Язык: Английский

---

Mesenchymal Stromal Cells as a Driver of Inflammaging

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(7), С. 6372 - 6372

Опубликована: Март 28, 2023

Life expectancy and age-related diseases burden increased significantly over the past few decades. Age-related conditions are commonly discussed in a very limited paradigm of depleted cellular proliferation maturation with exponential accumulation senescent cells. However, most recent evidence showed that majority age-associated ailments, i.e., diabetes mellitus, cardiovascular neurodegeneration. These closely associated tissue nonspecific inflammation triggered controlled by mesenchymal stromal cell secretion. Mesenchymal cells (MSCs) known as common type for therapeutic approaches clinical practice. Side effects complications MSC-based treatments interest MSCs secretome an alternative concept validation tests regenerative medicine. The data also proposed it ideal tool cell-free therapy engineering. was shown to hold role ‘key-driver’ inflammaging. We aimed review immunomodulatory MSCs-secretome during senescence provide eventual insight into interpretation its beneficial biological actions inflammaging-associated diseases.

Язык: Английский

---

Mesenchymal stromal cell derived extracellular vesicles as a therapeutic tool: immune regulation, MSC priming, and applications to SLE

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Фев. 8, 2024

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by dysfunction of the immune system. Mesenchymal stromal cell (MSCs) derived extracellular vesicles (EVs) are nanometer-sized particles carrying diverse range bioactive molecules, such as proteins, miRNAs, and lipids. Despite methodological disparities, recent works on MSC-EVs have highlighted their broad immunosuppressive effect, thus driving forwards potential in treatment diseases. Nonetheless, mechanism action still unclear, better understanding needed for clinical application. Therefore, we describe this review molecules mediating immunomodulatory techniques possibilities enhancing activity, finally application to SLE.

Язык: Английский

---

Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials

Stem Cell Research & Therapy, Год журнала: 2025, Номер 16(1)

Опубликована: Фев. 11, 2025

This study aims to assess the effectiveness and safety of mesenchymal stem cell (MSC) transplantation in treatment autoimmune rheumatic immune diseases through randomized controlled trials (RCTs). Two researchers conducted a comprehensive search Chinese English databases from their inception until Dec. 2023. The literature screening data extraction were then performed. Statistical analysis was carried out using RevMan 5.4 software. A total 42 relevant RCTs, involving 2,183 participants, ultimately included this study. These RCTs encompassed four types bone diseases, namely rheumatoid arthritis (RA), osteoarthritis (OA), spondyloarthritis, systemic sclerosis arthritis, lupus erythematosus (SLE), inflammatory bowel disease, multiple sclerosis, primary Sjögren's syndrome (PSS). systematic review indicates that MSC may improve RA, PSS. meta-analysis reveals significantly improved symptoms patients with OA [VAS (visual analogue scale): marrow: SMD = − 0.95, 95% CI 1.55 0.36, P 0.002; umbilical cord: 1.25, 2.04 0.46, adipose tissue: -1.26, -1.99 0.52, 0.0009)], SLE [Systemic disease activity index (SLEDAI): 2.32, 3.59 1.06, 0.0003], [clinical efficacy: RR 2.02, 1.53 2.67, < 0.00001]. However, not (Ssc). Importantly, did increase incidence adverse events (OA: 1.23, 0.93 1.65, 0.15; SLE: 0.83, 0.28 2.51, 0.76; Inflammatory disease: 0.99, 0.81 1.22, 0.96; Multiple sclerosis: 1.12, 1.53, 0.50), supporting its profile across studies. findings suggest holds promise for several while highlighting areas where further research is warranted. have potential treat diseases. Moreover. appears be relatively safe could considered as viable alternative option

Язык: Английский

---

Preparation of Recombinant Human Collagen III Protein Hydrogels with Sustained Release of Extracellular Vesicles for Skin Wound Healing

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(11), С. 6289 - 6289

Опубликована: Июнь 3, 2022

Existing treatment methods encounter difficulties in effectively promoting skin wound healing, making this a serious challenge for clinical treatment. Extracellular vesicles (EVs) secreted by stem cells have been proven to contribute the regeneration and repair of tissue, but they cannot be targeted sustained, which seriously limits their current therapeutic potential. The recombinant human collagen III protein (rhCol III) has advantages good water solubility, an absence hidden viral dangers, low rejection rate stable production process. In order achieve site-specific sustained release EVs, we prepared rhCol hydrogel cross-linking with transglutaminase (TGase) from Streptomyces mobaraensis, uniform pore size biocompatibility. profile III-EVs confirmed that could slowly EVs into external environment. Herein, promoted macrophage changing type M1 M2, migration ability L929 angiogenesis umbilical vein endothelial (HUVECs). Furthermore, is shown promote healing inhibiting inflammatory response cell proliferation diabetic rat injury model. reported results indicate used as new biological material EV delivery, significant application value healing.

Язык: Английский

---

Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy

Tissue Engineering and Regenerative Medicine, Год журнала: 2023, Номер 20(2), С. 157 - 175

Опубликована: Янв. 13, 2023

Язык: Английский

---